share_log

Novo-Nordisk A/S | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcement ·  Jan 31 20:03
Summary by Futu AI
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in financial performance for the period from January 1, 2023, to December 31, 2023. The company's sales surged by 31% in Danish kroner and 36% at constant exchange rates (CER), reaching DKK 232.3 billion. The operating profit followed suit, with a 37% increase in Danish kroner and a 44% rise at CER, amounting to DKK 102.6 billion. North America Operations saw a remarkable 50% growth in sales, while International Operations experienced an 11% increase. The Diabetes and Obesity care segment was a major contributor to this growth, with sales rising by 38% to DKK 215.1 billion, driven by GLP-1 diabetes sales and a staggering 147% increase in Obesity care sales. However, Rare disease sales saw a decrease of 16%. Novo Nordisk also...Show More
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in financial performance for the period from January 1, 2023, to December 31, 2023. The company's sales surged by 31% in Danish kroner and 36% at constant exchange rates (CER), reaching DKK 232.3 billion. The operating profit followed suit, with a 37% increase in Danish kroner and a 44% rise at CER, amounting to DKK 102.6 billion. North America Operations saw a remarkable 50% growth in sales, while International Operations experienced an 11% increase. The Diabetes and Obesity care segment was a major contributor to this growth, with sales rising by 38% to DKK 215.1 billion, driven by GLP-1 diabetes sales and a staggering 147% increase in Obesity care sales. However, Rare disease sales saw a decrease of 16%. Novo Nordisk also completed significant clinical trials, including the first phase 3a trial with IcoSema and a phase 1 trial with oral amycretin. Looking ahead to 2024, the company anticipates sales growth of 18-26% at CER and operating profit growth of 21-29% at CER. The Board of Directors plans to propose a final dividend of DKK 6.40 per share for 2023 at the Annual General Meeting on March 21, 2024, and has initiated a new share repurchase programme of up to DKK 20 billion.

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.